

## Ipsen mourns the passing of Henri Beaufour, a founding family Board member

**PARIS, FRANCE, 1 DECEMBER 2025** – It is with great sadness that Ipsen (Euronext: IPN; ADR: IPSEY) today announces that Henri Beaufour, Ipsen Board Member and a representative of the founding family, passed away on Friday, 28 November 2025.

Henri Beaufour, together with his sister Anne Beaufour, played a pivotal role in supporting the company's strategic direction and upholding the values established by the Beaufour family. The Board of Directors and Executive Leadership Team extend their heartfelt condolences to the Beaufour family and all who were touched by his life and work.

In their capacity as controlling shareholders, Beech Tree and Highrock reiterate their intent to continue to act together in the best interests of the Ipsen group and to support its ongoing development.

"As a long-serving member of our Board of Directors, a major shareholder, and a cherished member of the founding family, Henri Beaufour will be fondly remembered. Henri was not only a dedicated Director who played a significant role in the growth and development of Ipsen, but also an accomplished artist who upheld the values of his grandfather, the founder of the company. He was widely recognized for his generosity, kindness and profound humanity. Together, the Board of Directors is committed to pursuing its efforts in supporting Ipsen's strategy and priorities initiated under the aegis of his late father Albert Beaufour", said Marc de Garidel, Chairman of Ipsen.

"We are deeply saddened by the passing of Henri Beaufour. Myself, along with my leadership team and all of us at Ipsen, stand behind his family and the Board members in these sad moments. We will continue to drive and grow Ipsen in his memory", said David Loew, Chief Executive Officer.

### About Ipsen

We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries.

Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit [ipsen.com](https://www.ipsen.com).

### Ipsen Contacts

#### Investors

Henry Wheeler	<a href="mailto:henry.wheeler@ipsen.com">henry.wheeler@ipsen.com</a>	+33 764471149
Khalid Deojee	<a href="mailto:khalid.deojee@ipsen.com">khalid.deojee@ipsen.com</a>	+33 666019526

## Media

Sally Bain	sally.bain@ipsen.com	+1 8573200517
Anne Liontas	anne.liontas.ext@ipsen.com	+33 767347296

## Disclaimers and/or forward-looking statements

The forward-looking statements, objectives and targets contained herein are based on Ipsen's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words 'believes', 'anticipates' and 'expects' and similar expressions are intended to identify forward-looking statements, including Ipsen's expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation and risks arising from unexpected regulatory or political changes such as changes in tax regulation and regulations on trade and tariffs, such as protectionist measures, especially in the United States; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen's patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen's activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen's partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen's business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen's business is subject to the risk factors outlined in its registration documents filed with the French *Autorité des Marchés Financiers*. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen's latest Universal Registration Document, available on [ipsen.com](http://ipsen.com).